What's in Community Research Initiative of New England's pipeline?

Community Research Initiative of New England has 8 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Community Research Initiative of New England's portfolio?

Top competitors by shared drug class: Juan A. Arnaiz, Bristol-Myers Squibb, French National Agency for Research on AIDS and Viral Hepatitis, DualityBio Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/community-research-initiative-of-new-england.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Community Research Initiative of New England — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Community Research Initiative of New England pipeline: 8 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Darunavir (DRV/r)	Darunavir (DRV/r)	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
Increased dose of Kaletra	Increased dose of Kaletra	marketed
Intermitent Dosing	Intermitent Dosing	marketed
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase	Infectious Disease / Virology
Raltegravir plus Truvada	Raltegravir plus Truvada	marketed
continue on current dual boosted PI	continue on current dual boosted PI	marketed	Protease inhibitor (PI) combination with pharmacokinetic booster	HIV protease	Infectious Disease / Virology
atazanavir/raltegravir	atazanavir/raltegravir	marketed	Antiretroviral combination (protease inhibitor + integrase inhibitor)	HIV protease and HIV integrase	Infectious Disease
DRV/r	DRV/r	marketed	Protease inhibitor (boosted)	HIV protease	Infectious Disease

Therapeutic area mix

Infectious Disease · 3
Infectious Disease / Virology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Juan A. Arnaiz · 3 shared drug classes
Bristol-Myers Squibb · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
DualityBio Inc. · 1 shared drug class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
Far East Bio-Tec Co., Ltd · 1 shared drug class
Drugs for Neglected Diseases · 1 shared drug class
Baqiyatallah Medical Sciences University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Community Research Initiative of New England:

Cite this brief

Drug Landscape (2026). Community Research Initiative of New England — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/community-research-initiative-of-new-england. Accessed 2026-05-17.